Do Optimal Prognostic Thresholds in Continuous Physiological Variables Really Exist? Analysis of Origin of Apparent Thresholds, with Systematic Review for Peak Oxygen Consumption, Ejection Fraction and BNP

被引:31
作者
Giannoni, Alberto [1 ,2 ]
Baruah, Resham [1 ]
Leong, Tora [1 ]
Rehman, Michaela B. [4 ]
Pastormerlo, Luigi Emilio [2 ]
Harrell, Frank E. [5 ]
Coats, Andrew J. S. [1 ,3 ]
Francis, Darrel P. [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Int Ctr Circulatory Hlth, London, England
[2] Fdn Toscana G Monasterio, Dept Cardiovasc Med, Pisa, Italy
[3] Univ E Anglia, Norfolk & Norwich Hosp, Norwich NR4 7TJ, Norfolk, England
[4] Univ Poitiers Hosp, Dept Cardiol, Poitiers, France
[5] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA
来源
PLOS ONE | 2014年 / 9卷 / 01期
关键词
CONGESTIVE-HEART-FAILURE; BRAIN NATRIURETIC PEPTIDE; CARDIAC TROPONIN-T; RISK STRATIFICATION; RATE-VARIABILITY; CARDIOVASCULAR MORTALITY; VENTRICULAR-ARRHYTHMIAS; INDEPENDENT PREDICTOR; AMBULATORY PATIENTS; EXERCISE CAPACITY;
D O I
10.1371/journal.pone.0081699
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Clinicians are sometimes advised to make decisions using thresholds in measured variables, derived from prognostic studies. Objectives: We studied why there are conflicting apparently-optimal prognostic thresholds, for example in exercise peak oxygen uptake (pVO(2)), ejection fraction (EF), and Brain Natriuretic Peptide (BNP) in heart failure (HF). Data Sources and Eligibility Criteria: Studies testing pVO(2), EF or BNP prognostic thresholds in heart failure, published between 1990 and 2010, listed on Pubmed. Methods: First, we examined studies testing pVO(2), EF or BNP prognostic thresholds. Second, we created repeated simulations of 1500 patients to identify whether an apparently-optimal prognostic threshold indicates step change in risk. Results: 33 studies (8946 patients) tested a pVO(2) threshold. 18 found it prognostically significant: the actual reported threshold ranged widely (10-18 ml/kg/min) but was overwhelmingly controlled by the individual study population's mean pVO(2) (r = 0.86, p<0.00001). In contrast, the 15 negative publications were testing thresholds 199% further from their means (p = 0.0001). Likewise, of 35 EF studies (10220 patients), the thresholds in the 22 positive reports were strongly determined by study means (r = 0.90, p<0.0001). Similarly, in the 19 positives of 20 BNP studies (9725 patients): r = 0.86 (p<0.0001). Second, survival simulations always discovered a "most significant" threshold, even when there was definitely no step change in mortality. With linear increase in risk, the apparently-optimal threshold was always near the sample mean (r = 0.99, p<0.001). Limitations: This study cannot report the best threshold for any of these variables; instead it explains how common clinical research procedures routinely produce false thresholds. Key Findings: First, shifting (and/or disappearance) of an apparently-optimal prognostic threshold is strongly determined by studies' average pVO(2), EF or BNP. Second, apparently-optimal thresholds always appear, even with no step in prognosis. Conclusions: Emphatic therapeutic guidance based on thresholds from observational studies may be ill-founded. We should not assume that optimal thresholds, or any thresholds, exist.
引用
收藏
页数:16
相关论文
共 106 条
  • [51] High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure
    Lamblin, N
    Mouquet, F
    Hennache, B
    Dagorn, J
    Susen, S
    Bauters, C
    de Groote, P
    [J]. EUROPEAN HEART JOURNAL, 2005, 26 (21) : 2245 - 2250
  • [52] Recommendations for chamber quantification: A report from the American Society of Echocardiography's guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology
    Lang, RM
    Bierig, M
    Devereux, RB
    Flachskampf, FA
    Foster, E
    Pellikka, PA
    Picard, MH
    Roman, MJ
    Seward, J
    Shanewise, JS
    Solomon, SD
    Spencer, KT
    Sutton, MS
    Stewart, WJ
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY, 2005, 18 (12) : 1440 - 1463
  • [53] LIKOFF MJ, 1987, AM J CARDIOL, V59, P634
  • [54] VALUE OF PEAK EXERCISE OXYGEN-CONSUMPTION FOR OPTIMAL TIMING OF CARDIAC TRANSPLANTATION IN AMBULATORY PATIENTS WITH HEART-FAILURE
    MANCINI, DM
    EISEN, H
    KUSSMAUL, W
    MULL, R
    EDMUNDS, LH
    WILSON, JR
    [J]. CIRCULATION, 1991, 83 (03) : 778 - 786
  • [55] Systolic dysfunction is a predictor of long term mortality in men but not in women with heart failure
    Martínez-Sellés, M
    Robles, JAG
    Prieto, L
    Muñoa, MD
    Frades, E
    Díaz-Castro, O
    Almendral, J
    [J]. EUROPEAN HEART JOURNAL, 2003, 24 (22) : 2046 - 2053
  • [56] Direct comparison of B-Type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: The valsartan heart failure (Val-HeFT) data
    Masson, Serge
    Latini, Roberto
    Anand, Inder S.
    Vago, Tarcisio
    Angelici, Laura
    Barlera, Simona
    Missov, Emil D.
    Clerico, Aldo
    Tognoni, Gianni
    Cohn, Jay N.
    [J]. CLINICAL CHEMISTRY, 2006, 52 (08) : 1528 - 1538
  • [57] Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population
    McDonagh, TA
    Cunningham, AD
    Morrison, CE
    McMurray, JJV
    Ford, I
    Morton, JJ
    Dargie, HJ
    [J]. HEART, 2001, 86 (01) : 21 - 26
  • [58] Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates - 2006
    Mehra, Mandeep R.
    Kobashigawa, Jon
    Starling, Randall
    Russell, Stuart
    Uber, Patricia A.
    Parameshwar, Jayan
    Mohacsi, Paul
    Augustine, Sharon
    Aaronson, Keith
    Barr, Mark
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2006, 25 (09) : 1024 - 1042
  • [59] SURVIVAL OF IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR RECIPIENTS - ROLE OF LEFT-VENTRICULAR FUNCTION AND ITS RELATIONSHIP TO DEVICE USE
    MEHTA, D
    SAKSENA, S
    KROL, RB
    [J]. AMERICAN HEART JOURNAL, 1992, 124 (06) : 1608 - 1614
  • [60] Ventilatory variables are strong prognostic markers in elderly patients with heart failure
    Mejhert, M
    Linder-Klingsell, E
    Edner, M
    Kahan, T
    Persson, H
    [J]. HEART, 2002, 88 (03) : 239 - 243